Resources from the same session
Chair’s welcome and introductions
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
Presenter: Thomas Herzog
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Optimising clinical outcomes: the case for personalised medicine in ovarian cancer
Presenter: Ignace Vergote
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Summary and meeting close
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Broadening horizons: new data and combinations with PARP inhibitors
Presenter: Isabelle Ray-Coquard
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast